Domagrozumab Explained

Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.^{[1] [2]}

This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.^[3]

References

1. http://www.ama-assn.org/resources/doc/usan/x-pub/domagrozumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab
2. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 . WHO Drug Information . 29 . 4 . 2015 .
3. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_terminates_domagrozumab_pf_06252616_clinical_studies_for_the_treatment_of_duchenne_muscular_dystrophy